Have Insiders Sold Bristol-Myers Squibb Shares Recently?

Anyone interested in Bristol-Myers Squibb Company (NYSE:BMY) should probably be aware that the Independent Director, Julia Haller, recently divested US$241k worth of shares in the company, at an average price of US$63.31 each. That sale was 11% of their holding, so it does make us raise an eyebrow.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

The Last 12 Months Of Insider Transactions At Bristol-Myers Squibb

The Executive VP, Cristian Massacesi, made the biggest insider sale in the last 12 months. That single transaction was for US$403k worth of shares at a price of US$64.57 each. So we know that an insider sold shares at around the present share price of US$62.32. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

In the last year Bristol-Myers Squibb insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Bristol-Myers Squibb

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does Bristol-Myers Squibb Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Bristol-Myers Squibb insiders own about US$68m worth of shares. That equates to 0.05% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Bristol-Myers Squibb Insiders?

Insiders sold Bristol-Myers Squibb shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. But since Bristol-Myers Squibb is profitable and growing, we're not too worried by this. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Bristol-Myers Squibb. For example, Bristol-Myers Squibb has 3 warning signs (and 1 which is potentially serious) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.